直接抗病毒药物时代丙型肝炎病毒相关肝细胞癌的诊治对策

Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs

慢性丙型肝炎(CHC)隐匿进展是导致肝硬化和肝细胞癌(HCC)的主要原因之一。近年来,随着直接抗病毒药物(DAAs)的问世,CHC尤其是特殊人群包括进展期肝病和HCC的抗病毒治疗取得了巨大进展。DAAs和HCC的相关问题也成为目前CHC治疗的重要关注点之一。现就近年来丙型肝炎相关HCC诊治的最新研究进展进行综述。

The occult progression of chronic hepatitis C(CHC)is one of the main causes of liver cirrhosis and hepatocellular carcinoma(HCC).Recently,antiviral treatment of CHC has achieved great progress with the advent of direct-acting antiviral drugs(DAA),especially for special populations including advanced liver disease and HCC.However,DAA and HCC-related issues have also become one of the important concerns of current CHC treatment.This article summarizes the recent research progresses made in the diagnosis and treatment of HCV-related HCC.